{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=19", "query": { "intervention": "docetaxel", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 1320, "total_pages": 132, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:58:42.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01798485", "title": "A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Adenocarcinoma", "Non-small Cell Lung Cancer Stage IIIB", "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 696, "start_date": "2013-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 78, "location_summary": "Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798485" }, { "nct_id": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-06-25", "completion_date": "2018-05-29", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 16, "location_summary": "Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02131064" }, { "nct_id": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Female", "Breast Cancer", "Breast Cancer Metastatic", "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Phesgo", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab Subcutaneous Subcutaneous", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2024-08-08", "completion_date": "2033-03-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06439693" }, { "nct_id": "NCT00085826", "title": "A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Exisulind", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": null, "summary": "Not listed" }, "enrollment_count": 600, "start_date": "2001-04", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2011-10-20", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 92 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085826" }, { "nct_id": "NCT00028483", "title": "Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cBR96-doxorubicin immunoconjugate", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2011-10-24", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028483" }, { "nct_id": "NCT01957007", "title": "A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "vantictumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 34, "start_date": "2013-09", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 3, "location_summary": "Aurora, Colorado • Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01957007" }, { "nct_id": "NCT01282463", "title": "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of Urinary Tract", "Urethral Carcinoma", "Carcinoma of Ureter", "Carcinoma of Renal Pelvis" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Ramucirumab DP", "type": "BIOLOGICAL" }, { "name": "Icrucumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2011-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282463" }, { "nct_id": "NCT01234025", "title": "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castrate-Resistant Prostate Cancer" ], "interventions": [ { "name": "ISIS EIF4E Rx", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 113, "start_date": "2010-11", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 11, "location_summary": "Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "San Bernardino", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234025" }, { "nct_id": "NCT02486718", "title": "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1280, "start_date": "2015-10-31", "completion_date": "2026-08-26", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 45, "location_summary": "Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02486718" }, { "nct_id": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Adenocarcinoma", "HER2 Gene Mutation" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nutrition questionnaires (optional)", "type": "OTHER" }, { "name": "stool and saliva samples (optional)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-02-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-26T07:58:42.072Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06123338" } ] }